Questions persist about use of contrast agents Omniscan and Magnevist

 - magnifying glass red question mark
Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

With a heightened awareness of the potential retention issues with certain gadolinium-based contrast agents, patients who feel they’ve been harmed are seeking support groups and agent manufacturers are facing more questions, according to an article from investigative journalism site ProPublica.

Both GE Healthcare, makers of Omniscan, and Bayer HealthCare, makers of Magnevist, said they are monitoring the situation but that studies had not yet proven a clinical impact associated with the retained gadolinium. For more from ProPublica, click the link below: